CME article
Neoadjuvant hormonal therapy: The Canadian experience

https://doi.org/10.1016/S0090-4295(97)00170-2Get rights and content

Abstract

Objective

To assess the effect of neoadjuvant combination therapy with the antiandrogen flutamide and a luteinizing-hormone-releasing hormone (LHRH) agonist administered for 3 months before radical prostatectomy, compared with surgery alone in early stage prostate cancer on histopathologic findings at surgery and serum prostate-specific antigen (PSA).

Methods

A sample of 161 randomly screened patients diagnosed as having stage B (134 patients) or C (27 patients) prostate cancer were randomly assigned to radical prostatectomy alone or to 3 months of neoadjuvant combination therapy with the antiandrogen flutamide and an LHRH agonist before radical prostatectomy.

Results

Neoadjuvant combination therapy before radical prostatectomy decreased cancer-positive surgical margins from 33.8% in the control group to only 7.8%, thus leaving 92.2% of patients with negative margins at surgery. A net 54% improvement of staging was observed in favor of combination therapy. Organ-confined disease, on the other hand, increased from 49.3% to 77.8% of patients after 3 months of combination therapy, for a 57.8% increase in the incidence of organ-confined disease. No cancer was found in 6 (6.7%) prostatectomy specimens from the treated group. A close correlation was found between serum PSA at diagnosis and the stage of the disease at surgery. Upstaging increased from 30% at serum PSA values of 0 to 3.0 ng/mL up to 100% at serum PSA values above 15 ng/mL.

Conclusions

Although long-term follow-up of these patients is required to determine the impact on survival, the marked influence of neoadjuvant combination therapy on the stage of the disease suggests the possibility of a major improvement in the morbidity and mortality from prostate cancer.

References (45)

  • EpsteinJI et al.

    Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended follow-up

    J Urol

    (1986)
  • LabrieF

    Endocrine therapy for prostate cancer

    Endocrinol Metab Clin North Am

    (1991)
  • ParkerSL et al.

    Cancer statistics 1996

    CA Cancer J Clin

    (1996)
  • BrownML et al.

    The economic burden of cancer

  • MonfetteG et al.

    Temporary combination therapy with flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer

  • LeeF et al.

    Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma

    Radiology

    (1989)
  • CoonerWH et al.

    Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen

    Urology

    (1990)
  • CatalonaWJ et al.

    Measurement of prostate-specific antigen in serum as a screening test for prostate cancer

    New Engl J Med

    (1991)
  • LabrieF et al.

    Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer

    J Urol

    (1992)
  • LeeF et al.

    Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer

    Cancer

    (1992)
  • LabrieF et al.

    Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen

    Clin Invest Med

    (1993)
  • LabrieF et al.

    Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide lupron: the first controlled and randomized trial

    Clin Invest Med

    (1993)
  • Cited by (88)

    • Approach to the Patient with High-Risk Prostate Cancer

      2017, Urologic Clinics of North America
      Citation Excerpt :

      There is also renewed interest in neoadjuvant therapy before surgery using new agents that can better achieve more complete androgen blockage. Older studies of neoadjuvant ADT failed to demonstrate an overall survival advantage, but these trials were limited by incomplete androgen ablation and overrepresentation of patients with low-risk cancer who were unlikely to die from their disease (such as men with Gleason 6 disease).58–70 New studies are focusing on complete androgen blockade (using agents such as abiraterone acetate and enzalutamide) in high-risk patients who are likely to fail local therapy.71–74

    • Surgical Management of Prostate Cancer

      2013, Hematology/Oncology Clinics of North America
      Citation Excerpt :

      Thus, finding TP5 has significant clinical consequences for post-RP patient management. Several studies have explored the use of neoadjuvant androgen deprivation therapy (ADT) before prostatectomy.103–110 The initial results were encouraging, with improvements in several pathologic characteristics.

    View all citing articles on Scopus
    View full text